Identity and synonyms
Not a single peptide; no single sequence should be published.
Mixture · Mixture or extract
Detailed molecular class: Peptide-containing mixture
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Proposed neurotrophic actions of a heterogeneous preparation.
Evidence and critical reading
Reported scientific and empirical uses
Cognition and neurology
Described for neurological recovery/nootropics; it is a mixture, not one peptide sequence.
Human evidence
CASTA enrolled 1070 acute stroke patients; the primary combined endpoint was neutral. Post hoc findings do not prove healthy cognitive enhancement.
Preclinical evidence
Mixture experiments cannot identify one active sequence.
Critical reading and limitations
CASTA included 1,070 patients and was neutral on primary outcomes; this is not dementia prevention or healthy cognitive enhancement.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Product-specific adverse effects/exclusions need national label verification; no universal mixture safety conclusion.
Equivalence between the studied pharmaceutical mixture and catalog vials is not established.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID22282884 · Randomized controlled trial
Acute ischemic stroke.
Hospital trial treatment.
CASTA did not significantly improve its primary combined outcome.
Post hoc subgroups do not establish routine benefit or healthy cognitive enhancement.
n = 1070
Trials attributed in the package
NCT00868283 · The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic StrokeRegistry status: CompletedLast update posted: December 15, 2023Query verification: October 16, 2026
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Cerebrolysin · 43 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07846488 · Combined Acupuncture-Based Therapy for Rehabilitation After Ischemic StrokeRegistry status: Not yet recruitingLast update posted: September 29, 2026Query verification: October 16, 2026
NCT06339411 · Cerebrolysin After Reperfusion in Extended-window EndoVascular ThrombectomyRegistry status: Not yet recruitingLast update posted: August 11, 2026Query verification: October 16, 2026
NCT04427241 · Efficacy and Safety of Cerebrolysin on Prolonged Disorders of ConsciousnessRegistry status: RecruitingLast update posted: May 11, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID22282884
Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z, Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators.
October 16, 2026
- R49
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026